Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tissue Repair Ltd ( (AU:TRP) ) just unveiled an update.
Tissue Repair reported slower patient randomisation in its US Phase 3 trial of TR987 for chronic wounds, with about 40 patients enrolled so far and a goal of 100 by July 2026 to trigger an interim analysis that will determine whether the late-stage program continues. The company also confirmed the FDA will classify TR987 as a drug rather than a biologic, while signalling that if interim trial goals are not met it will curtail the Phase 3 program and pivot more aggressively to commercialising its TR Pro+ wound care product line. In parallel, Tissue Repair is ramping up TR Pro+ distribution via a partnership with Advanced Cosmeceuticals in Australia, expecting a sales uplift once a full range of SKUs becomes available in March 2026, and pursuing regulatory approvals, including 510(k) and CE marks, to support global market entry. The company is expanding its Glucoprime-powered wound and skin care portfolio, securing new distribution in Thailand, and progressing discussions with partners in the US, EU and Southeast Asia, while managing quarterly cash outflows driven by R&D and manufacturing costs with a cash balance of $8.229 million at 31 December 2025.
The most recent analyst rating on (AU:TRP) stock is a Hold with a A$0.30 price target. To see the full list of analyst forecasts on Tissue Repair Ltd stock, see the AU:TRP Stock Forecast page.
More about Tissue Repair Ltd
Tissue Repair Limited is an ASX-listed biotech company focused on wound healing and dermatology, developing both prescription drug candidates and over-the-counter products. Its lead assets include TR987, a drug for chronic wound treatment, and the TR Pro+ product line, which targets aesthetic, dermatology and broader wound care markets, with an emerging international commercialization strategy spanning the US, Europe and Asia.
Average Trading Volume: 85,045
Technical Sentiment Signal: Buy
Current Market Cap: A$19.35M
For a thorough assessment of TRP stock, go to TipRanks’ Stock Analysis page.